摘要
【目的】观察贝伐珠单抗联合5-氟尿嘧啶（5-Fu）＋亚叶酸钙（LV）＋奥沙利铂（L-OHP）（FOLFOX4）化疗方案治疗晚期直肠癌的临床效果。【方法】86例晚期直肠癌患者随机均分为对照组与观察组，各43例，两组均接受FOLFOX4一线化疗方案，观察组在此基础上加用贝伐珠单抗治疗，比较两组治疗效果，毒副反应，生存率。并采用结直肠癌生活质量评价表（EORTC QLC-CR37）评定患者治疗前后生活质量的改善情况。【结果】①观察组治疗总有效率高于对照组（P〈0．05）；②两组毒副反应发生率相比较差异无显著性（P〉0．05）；③随访2年，观察组总生存率高于对照组（P〈0．05）；④治疗后3、6、12、24个月，两组生活质量评分均降低（P〈0．05），观察组评分降低幅度均高于对照组（P〈0．05）。【结论】采用贝伐珠单抗联合FOLFOX4化疗治疗晚期直肠癌患者，总有效率高，同时可提高患者两年生存率，优化其生活质量。
[Objective]To observe the clinical effect of bevacizumab combined with 5-fluorouracil （5-Fu）, leucovorfn （LV） and oxaliplatin （L-OHP） （FOLFOX4） chemotherapy regimen in the treatment of advanced rectal cancer. [Methods]Eighty-six patients with advanced rectal cancer who were admitted to our hospital were selected as study subjects. According to order of hospitalization, the subjects were numbered and were randomized into a control group and an observation group, with 43 cases in each group. Both groups received FOLFOX4 first-line chemotherapy. The observation group was treated with bevacizumab in addition to this. The treatment effects,toxicity and survival rate were compared between the two groups. Both groups were followed up for 2 years. The survival rate was recorded and the quality of life was evaluated by European organization for research and treatment of cancer quality of life questionnaire （EORTC QLC-CR37 ）. [Results]（1） The total response rate in the observation group was higher than that in the control group （ P 〈0.05）. （2） There was no significant difference in the incidence of toxic and side effects between the two groups （ P 〉0.05）. （3） After 2 years of follow-up, the overall survival rate of the observation group was higher than that of the control group （ P 〈0.05）. （4） After 3, 6, 12 and 24 months of treatment, the quality of life scores of both groups decreased （ P 〈0.05）, and the decrease in the observation group was greater than that in the control group （ P 〈0.05）. [Conclusion]The application of bevacizumab combined with FOLFOX4 chemotherapy in treatment of advanced rectal cancer has a high total response rate, can improve the 2-year survival rate of patients and can optimize the quality of life.
出处
《医学临床研究》
CAS
2016年第11期2107-2110,共4页
Journal of Clinical Research
